October 23, 2022 First face-to-face meeting of the Inspiring & Writing Group After the establishment of the Inspiring and Writing Group early in 2022, members of this working group met for the first time in person at the EF CLIF Headquarters in Barcelona, Spain, to present ancillary studies from CANONIC, PREDICT, and ACLARA.

BARCELONA—The Inspiring and Writing Group works across disciplines and brings together expertise in end-stage liver disease, liver transplantation, critical care, gut microbiome, hepatic vascular disorders, hepatic encephalopathy, acute kidney injury, and liver regeneration. On the first face-to-face meeting of the Inspiring and Writing Group, members which project proposal was successful in an internal call, presented the rationale behind their project and expected outcomes.

Paolo Angeli, Chair of the EASL-CLIF Consortium, encouraged the audience to share knowledge for the advancement of chronic liver disease research with great enthusiasm during the opening session.

Our Scientific Director, Rajiv Jalan, presented the future scientific directions of the EF CLIF highlighting the importance of cross-sector collaboration. Jalan called members of the Inspiring and Writing Group to contribute to help us bridge the gaps in the existing literature to provide the basis for new therapeutic solutions for patients with chronic liver failure.

Cristina Sánchez-Garrido, Head of the Data Management Center, provided a detailed description of study designs and case report forms for the studies CANONIC, PREDICT and ACLARA.

Our General Manager, Anna Bosch, presented the process for project proposal submission and evaluation by the Sample and Data Usage Committee.

Next, Thierry Gustot, Principal Investigator of CHANCE who serves as the Vice-Chair of the EASL-CLIF Consortium and Chair of the Inspiring and Writing Group, presented and overview and preliminary results of the CHANCE study – Liver transplantation in patients with cirrhosis and severe acute-on-chronic liver failure: Indications and outcomes.

Jonel Trebicka, Principal Investigator of PREDICT and Coordinator of the EU-funded project MICROB-PREDICT – Microbiome-based biomarkers to predict decompensation of liver cirrhosis and treatment response, presented the current status of this project and provided a comprehensive review of many other ancillaries of the PREDICT study.

Pierre-Emmanuel Rautou, Coordinator of the EU-funded project DECISION – Decompensated cirrhosis: Identification of new combinatorial therapies based on systems approaches, presented an overview of the project and shared some preliminary results based on data from former studies CANONIC, PREDICT and ACLARA.

After the presentations of recently approved projects, Gustot thanked members of the Inspiring and Writing Group for the collaborative effort and continued support during the closing session.


The European Foundation for the Study of Chronic Liver Failure (EF CLIF) is a private non-profit organization connecting biomedical researchers and healthcare professionals with each other, with patients and patient associations, and with society. The fundamental purpose of EF CLIF, reflected in its founding Statements of 2015, is to advance knowledge and promote research and education in liver disease to improve the prognosis of patients living with chronic liver disease.

The Foundation has made pioneering efforts in conducting a series of large, international prospective studies that have been instrumental in reclassifying the trajectory of patients with chronic liver failure and led to the clinical, prognostic and pathophysiological definition of the syndrome referred to as “acute-on-chronic liver failure” characterized by acute decompensation of cirrhosis, severe systemic inflammation, organ failures, and high short-term mortality. We are inspiring best clinical practices for the management of patients with chronic liver failure and promoting a more sustainable and equitable healthcare system.

Within the Foundation, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL- CLIF Consortium, a network of 117 tertiary care and university hospitals in 28 European countries. The Grifols Chair promotes translational studies in centers across Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers in 8 countries. Over the last five years, the Foundation has successfully expanded its geographical scope providing the context to support transcontinental collaborative research projects. The Global Projects chapter provides the framework to promote research in cirrhosis across the world with the aim to help to build consensus and ensure health equity worldwide.